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ABSTRACT 
 Embryonic stem cells (ESCs) are pluripotent, self-renewing cells. These cells can be used in applications 
such as cell therapy, drug discovery, disease modelling, and the study of cellular differentiation. In this 
experimental study, embryonic stem cells cultured in the laboratory and were amplified. Total RNA was 
extracted from cells and converted to cDNA by reverse transcription-polymerase chain reaction (RT-PCR). 
Then c-Myc gene was amplified by (PCR) and inserted into the pTZ57R/T vector. Ligated product was 
transformed into susceptible bacteria and transformed bacteria were screened on a selective medium. 
Plasmids extracted from bacteria and enzyme digestion to confirm the sequencing was performed. The 
cloned c-Myc gene can be used to prepare a gene cassette to produce stem cells from somatic cell. 
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INTRODUCTION 
Human ES (Embryonic Stem) cells may become 
an unlimited source of cells or tissues for 
transplantation therapies involving organs or 
tissues such as liver, nervous system, pancreas 
and blood. Despite a tremendous interest in ES 
cells, relatively little is known about what defines 
their pluripotency and what drives ES cells to 
differentiate into specific cell types. The 
development of the mammalian embryo is 
controlled by regulatory genes, some of which 
regulate the transcription of other genes [1,2]. 
These regulators activate or repress patterns of 
gene expression that mediate phenotypic changes 
during stem cell differentiation. 
 One of these regulatory genes is Myc (c-Myc) 
which encodes for a transcription factor. It is 
believed that it regulates expression of 15% of all 
genes through binding on Enhancer Box 
sequences (E-boxes) and recruiting histone 
acetyltransferases (HATs). This means that in 
addition to its role as a classical transcription 
factor, Myc also functions to regulate global 
chromatin structure by regulating histone 
acetylation both in gene-rich regions and at sites 
far from any known gene [3]. It can also act as a 
transcriptional repressor. For example, by binding 
Miz-1 transcription factor and displacing the p300 
co-activator, it inhibits expression of Miz-1 target 
genes. In addition, myc has a direct role in the 
control of DNA replication [4]. 
 Members of its family include the c-Myc, N-
Myc, and the L-Myc genes. Myc gene was first 
discovered in Burkitt's lymphoma patients. In 
Burkitt's lymphoma, cancer cells show 
chromosomal translocations, in which 
Chromosome 8 is frequently involved. Cloning 
the break point of the fusion chromosomes 
revealed a gene that was similar to 
myelocytomatosis viral oncogene (v-Myc). Thus, 
the new found cellular gene was named c-Myc. 
 Myc family of transcription factors contain 
bHLH/LZ (basic Helix-Loop-Helix/Leucine 
Zipper) domain. Myc protein, through its bHLH 
domain can bind to DNA, while the leucine zipper 
domain allows the dimerisation with its partner, 
Max, another bHLH transcription factor. The Myc 
oncoprotein dimerizes with its partner, Max, to 
bind DNA, activate transcription, and promote 
cell proliferation, as well as programmed cell 
death. Max also forms homodimers or 
heterodimers with its alternative partners, Mad 
and Mxi-1. These complexes behave as 
antagonists of Myc/Max through competition for 
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common DNA targets, and perhaps permit 
cellular differentiation [5]. 
 Myc is activated upon various mitogenic signals 
such as Wnt, Shh and EGF (via the MAPK/ERK 
pathway). By modifying the expression of its target 
genes, Myc activation results in numerous 
biological effects. The first to be discovered was its 
capability to drive cell proliferation (upregulates 
cyclins, downregulates p21), but it also plays a 
very important role in regulating cell growth 
(upregulates ribosomal RNA and proteins), 
apoptosis (downregulates Bcl-2), differentiation 
and stem cell self-renewal. Myc is a very strong 
proto-oncogene and it is very often found to be 
upregulated in many types of cancers. Myc 
overexpression stimulates gene amplification [6], 
presumably through DNA over-replication. The 
Myc proto-oncoprotein coordinates a number of 
normal physiological processes necessary for 
growth and expansion of somatic cells by 
controlling the expression of numerous target 
genes. Deregulation of Myc as a consequence of 
carcinogenic events enforces cells to undergo a 
transition to a hyper proliferative state. This 
increases the risk of additional oncogenic 
mutations that in turn can result in further tumor 
progression. However, Myc activation also 
provokes intrinsic tumor suppressor mechanisms 
including apoptosis, cellular senescence and DNA 
damage responses that act as barriers for tumor 
development. Myc thus possesses two seemingly 
contradictory ―faces‖ referred to as ―Yin and 
Yang‖[7]. 
 While endogenous Myc (c-myc) and Mycn (N-
myc) have been reported to be separately 
dispensable for murine embryonic stem cell 
(mESC) function, myc greatly enhances induced 
pluripotent stem (iPS) cell formation and 
overexpressed c-myc confers LIF-independence 
upon mESC. To address the role of myc genes in 
ESC and in pluripotency generally, they were 
conditionally knocked out for both c- and N-myc 
using myc doubly homozygously floxed mESC 
lines (cDKO). Both lines of myc cDKO mESC 
exhibited severely disrupted self-renewal, 
pluripotency, and survival along with enhanced 
differentiation. Chimeric embryos injected with 
DKO mESC most often completely failed to 
develop or in rare cases survived but with severe 
defects. The essential nature of myc for self-
renewal and pluripotency is at least in part 
mediated through orchestrating pluripotency-
related cell cycle and metabolic programs. 
Endogenous myc genes are essential for mESC 
pluripotency and self-renewal as well as providing 
the first evidence that myc genes are required for 
early embryogenesis, suggesting potential 
mechanisms of myc contribution to iPS cell 
formation [8].  
 The object of this study is to clone human c-Myc 
gene in order to be used in converting somatic cells 
into stem cells. 
 
MATERIALS AND METHODS 
Cell culture 
 In this study Human embryonic stem line, 
(hSCT1; Stem cell technology research center, 
Tehran, Iran) was cultured in DMEM-F12 
supplemented with 20% knockout serum 
replacement, 2 mM L-gluatamine, 1% nonessential 
amino acid, and 20 ng/ml human bFGF (all from 
Invitrogen), and 0.1 mM 2-mercaptoethanol 
(Sigma). Primary mouse embryonic fibroblasts 
(MEFs) were used as the feeder cells in passages 2-
4. Monolayer of feeders were grown in Dulbecco 
modified Eagle medium (DMEM; GIBCO) 
supplemented with 15% fetal calf serum (FCS; 
GIBCO), 2 mM L-glutamine (GIBCO), 25 U/mL 
penicillin, and 25 µg/mL streptomycin (GIBCO), 
to confluence in a T-flask and treated with 10 
µg/mL mitomycin-C (Sigma) for 2 h. hESC 
experiments were performed on passage 12 from 
initial establishment. The Cells were passaged 
every 3–5 days with 1 mg/ml collagen IV 
(Invitrogen). After PBS washing, the cells were 
dispersed by scraping and passaged on fresh 
inactivated MEFs with above mentioned culture 
medium. 
Cloning of c-Myc gene 
 Total RNA of cells was extracted by RNAfast kit 
(provided by National Research Center of Genetic 
Engineering and Biotechnology, Tehran, Iran) 
based on using guanidine isothiosyanate. The 
efficiency of RNA extraction was confirmed by 
1% agarose gel electrophoresis. Then, total RNA 
was stored in -70
°
C until using. For 
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accomplishment of reverse transcription (RT) 
reaction to obtain equivalent cDNA, we used 
expand first strand cDNA synthesis kit (Roche 
Molecular Biochemicals, Germany). In this kit, the 
RNase activity of reverse transcriptase enzyme 
(MuLv, moloney murin leukemia virus) has been 
eliminated due to existence of a mutation in C-
terminus of RT enzyme. 
 The sequence of c-Myc gene related to Human 
embryonic stem cell was extracted from GenBank. 
Then primer designing was performed by oligo 
(Table 1). The primers were used to amplify and 
cloning of the complete sequence of c-Myc gene.  
Table 1. The oligonucleotide primers used in the PCR assay 
Primers Sequence 
Forward: 5- ATGCCCCTCAACGTTAGCTTCA -3 
Reverse: 5- TTCCTTACTTTTCCTTACGCACA -3 
The annealing temperature for primers was set at 
52
°
C. The extension time was 60 seconds. B actin 
gene in all reactions was used as internal control. 
After the end of reaction the amount of 7 µl of the 
product was used to be run on 1% agarose gel 
electrophoresis and then staining results were 
compared with marker 1kbp (Fermentase). After 
all proprietary products, PCR product was 
purified and ligated into the cloning vector 
pTZ57R/T which then transformed into E. coli 
DH5α. On a medium containing antibiotic 
ampicillin, transformed bacteria were screened. 
PCR with specific primers was performed for 
some of the cloned hosts. The recombinant 




Cell culture result 
 The results of embryonic stem cells culture has 
been shown in figure 1. 
Gene cloning result 
 Proliferation area which code human c-Myc gene 
was provided in the presence of desired primers 
and 1320 bp PCR product of human c-Myc gene 
was obtained.  
 PCR Product after purification, was cloned in 
vector pTZ57R/T. PCR reaction of the plasmid on 
selective culture indicates some of these positive 
plasmids specific for the c-Myc primers. Results 
of the sequencing on plasmids extracted from 
positive plasmids (figure 2) and comparison with 
gene data bank confirmed cloning of this gene. 
  
 
Figure 1. Human Embryonic stem cell line. 
 
Figure 2. Plasmids extracted from hosts .Lane M: DNA 
molecular weight marker, Lane 1: Recombinant plasmid. 
Lane 2: Non recombinant plasmid. 
 
DISCUSSION 
 iPS cells, generated by introduction of Oct3/4, 
Sox2, Klf4 and c-Myc transcription factors into 
fibroblasts, share many properties with ES cells. 
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Additionally, contribution of iPS cells to live 
adult chimeric animals and germline transmission, 
clearly demonstrate that re-programming to cells 
very similar to pluripotent ES cells, was achieved. 
Pluripotent stem cells (ESCs and iPSCs) are of 
great interest for basic research and clinical 
applications because they are uniquely capable of 
self-renewal and differentiation into a large 
number of cell types. These cells make it possible 
for the first time to analyze the epigenetic control 
of pluripotency and differentiation. 
 Yamanaka and co-workers surprised the 
scientific community when they reported that 
both mouse embryonic fibroblasts and tail tip 
fibroblasts could be reprogrammed to a 
pluripotent state similar to that observed in 
embryonic stem (ES) cells, by retroviral 
transduction of just four genes. The discovery of 
these ‗induced pluripotent stem (iPS) cells‘ was 
generally regarded as a major development in 
stem cell research and gave new insights into the 
pathways involved in the maintenance of 
pluripotency. Due to the complexity of genetic 
and epigenetic changes involved in cell 
differentiation, it had been doubted if it would 
ever be possible to reprogram somatic cells to 
pluripotency. With the first successful cloning 
experiments in mammals, it was verified that such 
reprogramming was, indeed possible. However, 
the landmark discovery by Takahashi and 
Yamanaka less than a decade later signalled a 
development, which few expected so soon. 
 By definition, pluripotency is the ability of a cell 
to give rise to all cell types of an adult organism, 
without the self-organising capability to form the 
whole organism. In vivo, pluripotency is observed 
in early embryos while in vitro, pluripotency may 
be maintained in ES cells. ES cells may be 
harvested from the inner cell mass (ICM) of 
blastocyst stage embryos. These cells, which were 
first isolated from mouse embryos, can proliferate 
indefinitely and possess the potential to develop 
in an unrestricted manner. 
 In culture, the pluripotency of mouse ES cells 
must be maintained by addition of factors such as 
leukaemia inhibitory factor (LIF), which promote 
proliferation while preventing differentiation. 
Human ES cells lines have also been generated, 
and their potential as donor sources of specialised 
cells in cell transplantation therapies has been 
widely acknowledged. 
 However, some major concerns remain for ES 
cell transplantation. Tissue rejection due to the 
patients‘ immune response represents a real 
limitation of the use of ES cells for 
transplantation. Another concern is that in the 
process of isolating ES cells, human embryos are 
inevitably destroyed. This has been a source of 
constant controversy since the development of the 
first human ES cell lines, and it has become an 
important ethical and political issue. These 
problems may, however, be overcome by 
reprogramming differentiated cells to an ES cell-
like pluripotent state. Such cells could be 
customised for individual patients and used in the 
treatment of disease. 
 Improvements in methodologies for detecting 
gene expression in the early embryo have led to 
the identification of several genes that may be 
involved in the regulation of early developmental 
events. These include genes encoding growth 
factors, their receptors, and numerous 
transcription factors, among which c-Myc seems 
to play a major role [9]. Dalton‘s group 
demonstrated an essential role for c-myc in 
normal LIF signalling in mESCs and showed that 
enforced c-myc expression conferred LIF-
independent ESC growth [10], sparking great 
interest in myc function specifically in ESCs. 
Because Dalton had implicated myc in ESC 
function, the Yamanaka lab included myc in the 
pool of 24 candidates. Progress toward answering 
some key questions about myc function in iPS 
cell formation has now been reported in additional 
papers from the Yamanaka and Jaenisch groups. 
These studies report iPS cell production with a 
three-factor cocktail, that does not include myc, is 
also possible [11,12]. The efficiency of the iPS 
cell process without myc, is dramatically reduced 
and appears to progress much more slowly. 
Indeed, under standard antibiotic selection, the 
iPS cell process failed without myc. In half of the 
experiments conducted over an extended period 
of selection, no iPS cell colonies at all were 
produced when myc was excluded from the 
reprogramming protocol. An example of 
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successful iPS cell formation without myc, from 
adult tail tip fibroblasts, nonetheless yielded iPS 
cells with an almost 500-fold reduced efficiency, 
demonstrating that, at least under these assay 
conditions, myc fulfils an important role in the 
direct reprogramming process [11]. Thus, the 
ability to routinely and efficiently generate iPS 
cells may be myc dependent. Of great importance 
is the observation that mice generated from these 
three-factor iPS cells did not develop any tumours 
within 100 days [11], indicating that not all iPS 
cell-derived mice are prone to tumours. 
 But how could a proto-oncogene contribute to 
pluripotency or self-renewal of ESCs? Three 
models are proposed: (1) inducing a cell-cycle 
program necessary specifically for self-renewal, 
(2) modifying epigenetic patterns to promote 
dedifferentiation or block additional 
differentiation, and (3) selection of a rare 
population of cells with predetermined traits 
suited to permit induced pluripotency and self-
renewal [13]. According to first item, myc may 
induce a stem-like cell-cycle program in 
fibroblasts whereby myc represses CDKI and 
stimulates D cyclins. The unique cell-cycle 
regulatory pathway in ESCs may be explained by 
a combination of low CDKI levels, high Cdk2 
activity, and Rb hyperphosphorylation together 
maintained by elevated myc [10]. Also 
importantly, c-myc, albeit exogenous, sustained 
self-renewal in ESCs without strongly impinging 
on the cell cycle and was postulated to function 
by blocking differentiation [10]. According to the 
second item, myc contributes to iPS cell 
formation by inducing chromatin changes 
required for pluripotency [14] and according to 
third, it is also possible that among millions of 
fibroblasts lurk rare stem-like cells that are not 
fully differentiated and represent the only target 
cells amenable to direct reprogramming into iPS 
cell clones. 
 In the context of emerging regenerative 
medicine, myc has the potential to play a dual role 
in stem cells [13]. Levels of myc that are too high 
are likely to trigger apoptosis [10], whereas very 
low expression would inhibit induction of 
pluripotency. Thus the key to safely utilizing stem 
cells in regenerative medicine may reside in 
maintaining the appropriate expression levels, 
neither too high nor too low, of myc. 
 In the last decade, a number of methods have 
been found to induce pluripotency artificially in 
somatic cells, including somatic cell nuclear 
transfer (SCNT) and cell fusion. Much of the 
research in this area has been carried out with 
mice, but the ultimate goal of stem-cell scientists 
remains the production of patient-specific 
pluripotent cells and their use in treatment of 
disease. Because both SCNT and cell fusion have 
posed technical and ethical problems as methods 
of reprogramming somatic cells, Takahashi and 
Yamanaka‘s method of reprogramming by 
defined factors has been hailed as the ‗holy grail‘ 
of stem cell research. This method circumvents 
many of the problems associated with both SCNT 
and cell fusion and is regarded as the method with 
the best potential for producing patient-specific 
pluripotent stem cells for use in regenerative 
medicine [9].  
 Since the initial discovery of mouse iPS cells by 
Takahashi and Yamanaka, research in this area 
has advanced at an astonishing rate. In just over a 
year, the technology used to reprogram mouse 
cells has been successfully extended to human 
cells, while some of the initial problems with 
mouse iPS cells, including tumourigenicity have 
been partly addressed. Nevertheless, extensive 
research is still required with mouse iPS cells 
before any potential therapeutic use of human iPS 
cells is realised. The cause of the low efficiency 
of iPS induction remains to be determined. In 
addition to gene activation by expression of 
transcription factors, epigenetic remodelling plays 
a key role in induction of cellular pluripotency. A 
greater understanding of this mechanism will be 
necessary to improve the efficiency of iPS cell 
generation. Moreover, retroviral transduction 
involves random integration into the genome and 
consequently poses a risk of mutagenesis. The 
future use of alternative gene delivery systems or 
small molecules, which can replace retroviral 
gene products, may circumvent this problem. 
 Also, if iPS cells are to be used clinically, 
methods to direct differentiation and integrate 
them into tissues are still required. Despite this, 
however, iPS cells represent one of the best hopes 
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for producing patient-specific stem cells for cell-
based therapies. 
 With regard to the previous studies, we can 
conclude that c-Myc gene has a central role in 
maintaining pluripotency and self-renewing 
properties of iPS cells. Thus, it can be considered 
as one of the essential candidates in somatic cells 
reprogramming which is applicable in cell 
transplantation and treatment of diseases. 
Therefore, in this study, we cloned this gene to be 
used later along with other essential gene 
candidates in making a gene cassette to produce 
iPS cells from somatic cells. 
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